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Current perspectives
Complementary and alternative medicine for the allergist-
immunologist: Where do I start?
Renata J. M. Engler, MD, FAAAAI, FACAAI,a,b Catherine M. With, JD, LLM, LLM,c Philip J. Gregory, PharmD,d,f
and Jeff M. Jellin, PharmDd,e Washington, DC, Bethesda, Md, Omaha, Neb, and Stockton, Calif
Complementary and alternative medicine (CAM) therapies
present a growing information management challenge for
physicians because nearly 40% of their patients may be using and
another 50%may be considering use of CAM as part of their
healthcare regimen. The National Health Statistics Reports for
2007 described the most commonly used nonvitamin, nonmineral
therapy as natural products (eg, herbals at 17.7%).More than 5%
of children under the age of 18 years used CAM for allergic
conditions including asthma. The amount and quality of
information available and concerns about liability risk represent a
challenge for most physicians. This review focuses on
considerations for approaching a CAM-related consultation,
incorporating legal and logistic factors affecting how such an
encounter should be approached. A 10-step process is presented
that addresses different components of CAM consultations and
what should be documented. Access to timely, high-quality
information regarding product specific efficacy and safety data, as
found in the Natural Medicines Comprehensive Database, is
needed to support CAM consultation efficiently. Understanding of
serious adverse events associated with CAM is limited; an
international need exists for improved safety surveillance and
information sharing. Allergy-immunology, as a specialty with
expertise in adverse drug reaction evaluation and management,
has a unique opportunity to support enhanced CAM-related
adverse events evaluations, reporting, and research. (JAllergyClin
Immunol 2009;123:309-16.)
Key words: Complementary and alternative medicine, integrative
medicine, herbals, herbs, adverse reactions, risk communication,
quality of care
COMPLEMENTARY AND ALTERNATIVE MEDICINE
CHALLENGES FOR CLINICIANS
Health care workers trained in allopathic medicine frequently
encounter patients who expect patient-centric holistic care with a
potential to discuss complementary and alternative medicine
(CAM) therapies. This discussion is not a topic that is included in
any current medical competency training, and most health care
workers have limited knowledge on the subject. Unfortunately, if
there is a perceived reluctance or derogatory attitude from the
provider, the patient may use CAM therapies without informing
the health care team, potentially affecting the benefit and risk of
traditional medicines. Ironically, as traditional/conventional med-
ical practices are squeezed by reduced fees and insurance-related
barriers to care delivery, the world of CAM therapists and
therapies is enjoying an expanding market in which patients are
willing to pay out of pocket.1 In 2007, almost 4 of 10 adults had
used CAM therapy in the past 12 months, with the most com-
monly used therapies (nonvitamin, nonmineral) including natural
products (17.7%) and deep breathing exercises (12.7%).2 Al-
though mainstream physicians have confidence in the safety
and efficacy of evidence-based medical practices, and managed
care organizations cite such evidence in developing treatment
pathways, patients seeking CAM treatment are often distrustful
of these practices. The Institute of Medicine report on medical er-
rors3 shows that the safety of traditional medical practices can be
questioned. Furthermore, a recent literature review of published
managed care strategies designed to reduce cost and improve
the quality of medication demonstrated an adverse outcome: pa-
tients with chronic illness had reduced access to essential medi-
cines due to shift in the cost burden from the managed care
organization to the patient.4
Taken together, these factorsmay contribute to an atmosphere in
which patients may not fully discuss all therapeutic approaches
taken with their allopathic healthcare providers. The unintended
dilemma for the physician is a limited amount of time, energy, and
resources to focus on conventionalmedicine and a distrust ofCAM
therapies in the face of limited knowledge and predominantly
negative increased risk perceptions for unfamiliar CAM treat-
ments. The unintended dilemma for the patient, who has rapid
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access to a bewildering array of unfiltered information via the
Internet as well as vast promises of success through CAM (or
natural) therapies, is a perception that traditional medicine is
intimidating and unresponsive to holistic concerns, whereas CAM
therapies and therapists are more approachable and/or trustworthy.
Given the time and cost constraints found in mainstream
medicine, incorporating within the traditional medical encounter
the 6 interactive components of the patient-centered clinical
method (exploring both disease and the patients’ illness experi-
ence, understanding the whole person, finding common ground,
enhancing the patient-doctor relationship, being realistic, and
incorporating prevention and health promotion) is frequently
difficult.5 Ultimately, patients and their caregivers/guardians are
seeking to optimize their quality of life and well being as an out-
come with a desire to exhaust all treatment options that might
improve disease management. The search for ‘‘remembered well-
ness’’ (p 194) or what many perceive as the placebo effect is fre-
quently the focus of a patient-centric encounter.6 The measurable
clinical and quality of life benefits from the placebo effect may
represent at least a part of this ‘‘remembered wellness’’ outcome.
Allergy-immunology specialists are faced with the challenge of
how to respond practically to the evolving information presented
by the expanding world of CAM. The spectrum of positions on
CAM within conventional medical practices ranges from ‘‘don’t
ask, don’t tell’’ to establishing a partnership with the patient who
may be seeking or is already using CAM therapies. A small
percentage of practitioners are incorporating both conventional
and nontraditional medical therapies, reflecting a movement
toward integrative medicine. Many physicians and health care
workers in general are interested in learning more about CAM but
are overwhelmed by the amount of information and afraid of
entering into any discussions with their patients because of a
possible liability risk and/or time requirement. This review focuses
on practical considerations for approaching a CAM-related con-
sultation and incorporates updates on legal and logistic factors that
affect how such an encounter could be managed and documented.
RESPONSE TO PATIENTS SEEKING INFORMATION
ABOUT CAM THERAPIES
In 1997, Eisenberg7 published his landmark article titled ‘‘Ad-
vising patients who seek alternative medical therapies.’’ The
passionate responses in subsequent comment letters illustrate
the trepidation generated by Eisenberg’s step-by-step proposed
strategy whereby ‘‘conventionally trained medical providers
and their patients can proactively discuss the use or avoidance’’
(p 61) of CAM therapies. Concerns about time and expertise re-
quired, resource diversion from proven therapies, and physi-
cians’ ethical right to not participate in unproven therapies
were just some of the issues. Strategies for shared decision-mak-
ing that focused on doing no harm and documenting legally de-
fensible behavior on the part of the physician were detailed and
reinforced in subsequent articles, including an Institute of Med-
icine report titled ‘‘Complementary and Alternative Medicine in
the United States.’’8-11 It is noteworthy that the Institute of Med-
icine report was strongly contested by some,12 but for many cli-
nicians seeking more information and a more intellectually open
approach to the study of unconventional therapies (if indicated
by positive outcomes), the report represented a needed catalyst
for examining CAM therapies for useful and valuable therapeu-
tic options.13
In the past 10 years, the presence of CAM therapies in different
patient populations has increasingly affected a broad range of
medical specialties. The 2002 National Health Information
Survey, which was limited in the scope of CAM content, showed
that 36% of adults used CAM (62% if prayer was included), with
follow-up surveys demonstrating continued increases, particu-
larly in the use of herbals.1-2 At the same time, health care pro-
vider knowledge of CAM or awareness of CAM use by their
patients remains deficient, and an evolving need for a CAM-
focused education curriculum in medical schools and residencies
is presented in the literature.14-19 The fact that 50% of Americans
would consider trying CAM therapy in addition to conventional
therapies is a staggering statistic that makes the need for develop-
ing tools and resources to support clinicians in meeting this chal-
lenge ever more urgent. Avoidance and denial are no longer
sustainable options for conventional practitioners.1
PROPOSED 10-STEP APPROACH TO PATIENT-
PHYSICIAN PARTNERSHIPS IN EXPLORING
THERAPEUTIC ALTERNATIVES
Although Eisenberg’s work7-9 has laid significant ground work
for discussingCAM treatmentswith patients, controversy continues
surrounding the evolvingfiscal, ethical, and legal questions thatmay
accompany such discussion. It has been argued that use of CAM
treatments is analogous to the situation encountered when US
Food and Drug Administration (FDA)–approved drugs are used
for off-label indications. However, even when used for off-label in-
dications, FDA-approved therapies have undergone quality control
scrutiny and include a safety profile as required by the FDA
licensure requirements. In the CAM arena, products such as herbal
supplementsmaynot have beenmanufacturedwith stringent quality
controls, so content, amount, or contaminants present may be con-
founding variables that affect the outcome of a therapeutic trial.
There is a need for standardizing clinical guidelines to address
complex medical management, particularly when the level of
evidence for a wide range of therapeutic options is variable and
multidisciplinary competencies are involved. Yetwhen patients ask
that CAM approaches be included in medical management, there
are limited efficacy and safety data available to providers, andmost
CAM interventions have not been reviewed by broad-based
national expert panels, like theNationalHeart, Lung, andBlood In-
stitute panel, which has developed the National Asthma Education
and Prevention Programasthma care guidelines. TheNational Cen-
ter for Complementary and Alternative Medicine (NCCAM) at the
National Institute of Health (NIH) has supported the development
of expanded educational resources and funded research to address
the questions related to the efficacy and safety of specificCAMther-
apies that are necessary for informed clinical choices.20
Building on Eisenberg’s6 approach, this article’s Table E1 in
the Online Repository at www.jacionline.org presents a 10-step
summary of the critical elements to be considered in developing
a patient-provider partnership that includes CAM therapeutic
options.7,8 The key elements of physician-patient interactions
that involve CAM questions and/or therapeutic impact include
the following: (1) exploring factors driving interest in CAM; (2)
documenting clinical reasons for seeking CAM options; (3)
assessing current disease/health status and therapies to date; (4)
documenting patient’s preferences and reasons; (5) assessing
and documenting adequacy of medical evaluation; (6) defining a
plan for follow-up visits; (7) providing good risk communications
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with option for additional consultative visits; (8) acknowledging
evolving expectations and goals; (9) educating about new safety
and/or efficacy issues related to CAM choices during each visit;
and (10) addressing need for further consultations and how these
consultations can be optimized (see Table E2 in this article’s
Online Repository at www.jacionline.org). Nonetheless, signifi-
cant issues and controversies confront licensed conventional
health care providers when considering inclusion (or exclusion)
of elements of CAM therapy in medical decision-making. Physi-
cians cannot be forced to adapt any practice with which they do
not feel comfortable or they believe is harmful, futile, or too
much of an unknown. Providing consultation on CAM therapies
may be complex and time-consuming with an initial steep learn-
ing curve for both patient and physician. The growing questions
about reimbursement for such services cannot be ignored or min-
imized and require clarification because physicians are stressed
by the business of medicine.
TOOLS AND RESOURCES TO SUPPORT
GATHERING UP-TO-DATE INFORMATION ON THE
EFFICACY, SAFETY, AND DISEASE EXACERBATION
RISKS OF A CAM THERAPY
Gathering reliable, unbiased, and comprehensive data about
CAM therapies can be a challenge. In the early 1990s, when patient
use of CAM therapies began to accelerate across North America,
many clinicians sought data on these therapies to counsel patients
better, but there simply was not an easy way to find information. In
many cases, reliable information did not exist. It is noteworthy that
the first Physicians’ Desk Reference on herbal supplements did not
appearuntil 1998.21Today, the landscapehas changed, thanks toex-
panded research in the area of CAM and improved availability of
new resources with rapid cycle information updating.
One trustworthy source of information on a wide variety of
CAM treatments and interventions is the NCCAM of the NIH.
The NCCAM began as the Office for Alternative Medicine with a
Congressional funding allocation in 1991. Since that time,
support for objective research of CAM interventions has grown,
and in 1998, NCCAM was authorized in its current form by
Congress. NCCAM oversees a robust research portfolio designed
to identify promising CAM approaches and show safety and
efficacy. In addition, the NCCAM maintains a large database on
CAM treatments, and this is easily available to providers and
patients through the NCCAM website (http://nccam.nih.gov/).
The Natural Medicines Comprehensive Database is another
trustworthy resource for data on CAM treatments that was
developed by the publishers of Prescriber’s Letter and Pharma-
cist’s Letter in the mid-1990s.22 This database provides
evidence-based information (using standardized approach to evi-
dence quality/ranking23) on CAM that includes practical evi-
dence-based reviews on nearly 1100 natural ingredients
(representingmany thousands of different generic names, depend-
ing on the culture in which it is used) as well as supplements and
more than 30,000 commercially available brand name products. It
cites more than 16,000 references and includes reviews of more
than 2000 new scientific articles for potential inclusion every
year. This database includes evidence-based information on tradi-
tional Chinese medicine, Kampo medicine, Ayurvedic medicine,
and several alternative treatment modalities such as acupuncture,
reflexology, and many others. The database also provides an
evidence-based rating on commercially available CAM products
based entirely on the evidence for safety and effectiveness for pro-
duct ingredients plus evidence for product quality using data from
international regulatory bodies.
Research for the Natural Medicines Comprehensive Database
is critically assessed on the basis of key factors such as random-
ization, allocation concealment, adequate blind, and other factors
using the principles from the Cochrane Collaboration24 and is reg-
ularly maintained and updated. Research results are selected that
have the potential to provide relevant information related to
safety, effectiveness, and clinical use, mechanism of action or
pharmacology, interactions with drugs, laboratory test interfer-
ence, or other practice information that is relevant to health pro-
fessionals. After the initial search and review of the literature,
new research findings are identified through systematic searching
of literature for updated data on specific CAM approaches. Exam-
ples of information regarding CAM approaches for allergic dis-
eases, interactions of CAM treatments with FDA-approved
drugs, and CAM treatments that exacerbate allergic disease are
shown in Tables I to III. A more complete description of this da-
tabase can be found at http://www.naturaldatabase.com.
EMPOWERING THE PATIENT TO PARTNER IN THE
SEARCH FOR RELIABLE INFORMATION, ENABLING
THE CLINICIAN TO PRACTICE GOOD MEDICINE
SAFELY: LEGAL IMPLICATIONS AND ETHICS
There is concern about the potential legal liability of physicians
and other licensed providers when they choose to provide
consultation about or direct care with CAM treatments (either
individually or through an integrative medicine clinic environ-
ment) or refer their patients to nonphysician CAM providers.
Much of this discussion ignores the increasing focus on patient-
directed care and choice empowerment, positioning the provider
as a consultant, not as the person in charge. The ethical conundrum
comes when perceived legal liability drives a physician to refuse
care, only further enhancing the well documented and higher risk
behavior of don’t ask, don’t tell. What are the potential liability
risks when the physician does not want to abandon the patient but
wants to minimize risk for the practice? Liability is the legal
responsibility for one’s acts or omissions, and there are 2 primary
areas of liability concern for physicianswho choose to incorporate
CAM into their practices or refer patients to CAM providers.
The first is in the realm of health care licensure, which
determines who can be licensed. The extent of the scope of
practice varies among the jurisdictions and is a matter of state law.
Generally, the scope of practice for physicians in the United States
is unlimited, meaning that they can generally use all methods that
their profession accepts as safe and effective to treat a given
disease.25 Because the practice of medicine is licensed and regu-
lated at the state level, individual physicians are accountable to
their respective statemedical boards for the quality of care they de-
liver. If physicians choose to incorporate nontraditionalmethods in
their practices and provide patients with CAM therapies that are
unsafe and ineffective, theymay face allegations of unprofessional
conduct or may be disciplined by their respective state medical
boards should these physicians depart from the standard of care
(may be defined as any departure from acceptable and prevailing
medical practice) in that particular jurisdiction.26,27 CAM, under
some definitions, is considered a departure from conventional
norms of practice.28 Unlike the standard of care applied by courts
in medical malpractice cases, medical board disciplinary cases do
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not have to establish that themedical care under review caused any
injury to the patient.26 Therefore, physicians can be subject to li-
cense revocation even if there is no injury to the patient. Even
though disciplinary action for failure to meet the standard of care
is possible, most charges against physicians who practice CAM
tend to be related to ‘‘failure to perform adequate patient evalua-
tions, testing, monitoring, and record-keeping,’’ and generally
such failures are actions under the physician’s control26 (p 71).
To avoid charges of unprofessional conduct from their state
medical licensing boards, physicians must continue to monitor
patients conventionally and perform adequate evaluations, order
necessary tests, and document encounters carefully in the medical
record. Physicians are advised to follow the Federation of State
Medical Boards ‘‘guidelines for the use of complementary and
alternative therapies in medical practice.’’27,29
A second area of potential liability concern is the potential risk
of allegations of medical malpractice if the CAM treatment
provided to a patient falls below the standard of care and injures
the patient.27,30 Medical malpractice is governed by the law of
torts. A tort is any wrongful act that one person commits against
another, and a negligent tort is defined as a failure to exercise rea-
sonable care under the circumstances.31 Medical malpractice
based in negligence provides that liability likely exists when a
given therapy falls below the standard of care and subsequently
injures the patient.30
Ultimately the standard of care will be determined by expert
witness testimony in a court of law and is the same for all
physicians regardless of whether they use conventional or CAM
therapy.26,28,30 The standard of care is determined by whether a
particular treatment deviated from accepted medical practice in
TABLE I. Selected natural medicines used for atopic conditions
Natural medicine Use/indication Effectiveness rating Practice pearl
Bifidobacteria Eczema Possibly Effective Some evidence in infants only.
Bitter orange Asthma/allergic rhinitis Insufficient Evidence to Rate Bitter orange contains a stimulant similar to
ephedra; linked to several reports of severe
adverse events including myocardial infarction.
Butterbur Allergic rhinitis Possibly Effective Some evidence that a specific butterbur extract is
comparable to Zyrtec (cetirizine; McNeil-PPC,
Raritan, NJ) and Allegra (fexofenadine; Sanofi-
Aventis, Bridgewater, NJ); a specific extract
(Ze 339) standardized to 8 mg total petasine has
been used.
Choline Asthma Possibly Effective
Fish oil Asthma Possibly Effective Benefits seen in children but not adults.
Honey Allergic rhinitis Insufficient Evidence to Rate;
preliminary evidence suggests that
honey does not improve symptoms
Lactobacillus Eczema/atopic
disease
Possibly Effective Specific product used in clinical trials –
Lactobacillus GG (Culturelle, Amerifit Brands,
Cromwoll, Conn)
Magnesium Asthma Possibly Effective Intravenous magnesium beneficial for acute attacks;
by mouth magnesium supplements do not
improve chronic asthma.
Phleum pratense Allergic rhinitis Possibly Effective A specific standardized product (Grazax, ALK-
Abello´, Denmark) has been used.
Pycnogenol Asthma Possibly Effective Benefits seen in children.
Quercetin Asthma/allergic rhinitis Insufficient Evidence to Rate Thought to work similarly to cromolyn; however, no
clinical data to support use.
Serrapeptase Bronchitis, sinusitis Insufficient Evidence to Rate; preliminary
evidence suggests some benefit
Sinupret (Bionorica,
San Clemente, Calif)
Sinusitis Possibly Effective This is a brand name product containing 5 herbal
ingredients.
Stinging nettle Allergic rhinitis Insufficient Evidence to Rate; preliminary
evidence suggests some benefit.
If used, stinging nettle should be started at the first
sign of symptoms.
Tinospora cordifolia Allergic rhinitis Possibly Effective A specific extract (Tinofend, Verdure Sciences,
Noblesville, Ind) has been used.
Vitamin C/citrus fruits Asthma Insufficient Evidence to Rate; preliminary
evidence that eating vitamin C–rich fruits
1-2 times/wk improves lung function; some
conflicting data; preliminary evidence that
vitamin C supplements might decrease
exercise-induced asthma
Grapefruit, kiwi fruit, orange, and other fruits.
Whey protein Atopic disease Possibly Effective Some evidence in infants only.
From Jellin J, Gregory P, editors. Natural medicines comprehensive database. Stockton (CA): Therapeutic Research Faculty; 2008. Available at: http://www.naturaldatabase.com.22
Accessed January 1, 2009. Not a complete list. For additional data, go to http://www.naturaldatabase.com.
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the community.26 Because efficacy and safety data about CAM
therapies are often limited, the standard of care for CAM is
not as well defined as for conventional medicine.30 Courts may,
therefore, view a nonstandard CAM therapy as equivalent to
substandard therapy or care.28 To avoid allegations of medical
malpractice, physicians who wish to incorporate CAM therapies
into their practice must be familiar with the efficacy and safety
data relevant to the CAM therapy and must assure that it has
been addressed with the patient and a benefit-risk assessment for
the recommended use well documented.33
Information about the safety and efficacy of a specific CAM
therapy can be classified into 4 categories of relative potential
liability risks:30
1. Evidence supports both safety and efficacy of the CAM
therapy
2. Evidence supports safety of the CAM therapy, but evi-
dence regarding efficacy of the CAM therapy is
inconclusive
3. Evidence supports efficacy of the CAM therapy, but evi-
dence regarding safety of the CAM therapy is inconclusive
4. Evidence indicates either serious risk or inefficacy of the
CAM therapy
If a CAM treatment falls into category 1, liability risk is
minimized and probably comparable to the use of any other
conventional therapy. If a treatment falls within category 4,
liability risk is high, and defense of use would be difficult when
responding to a negligence allegation. However, most CAM
therapies fall into categories 2 and 3, with the issue of safety more
important than efficacy.27 Evidence regarding any specific CAM
therapy safety and efficacy may change with evolving research,
so it is important to recognize that the risk category of a CAM
therapy may change over time.
To minimize the potential for medical malpractice liability,
physicians who choose to use CAM therapies should consider
incorporating the following strategies within the treatment
regimen:26,27,30
1. Determine and document the clinical risk level by review-
ing existing medical literature to assess the evidence for
safety and efficacy of a given CAM therapy
2. Provide adequate informed consent by engaging in a clear
discussion of the risks and benefits of using the CAM ther-
apy and document informed consent process
3. Continue to monitor the patient during conventional and
CAM therapies
4. If aCAMtherapist is involved, advise thepatient to seekobjec-
tive information about the provider and report adverse events
There is potential medical malpractice liability when a con-
ventional provider refers their patient to a nonphysician CAM
provider and/or functions in a team approach with implied
supervisory responsibility or integrated medical practice. Gener-
ally, courts have been reluctant to impose liability for a referral to
another provider, but there exist notable exceptions.32 Vicarious
TABLE II. Potential interactions between selected natural medicines used for atopic conditions and conventional medicines
Natural medicine Interactions Mechanism Interaction rating
Bitter orange QT-interval–prolonging drugs
Stimulant drugs
Bitter orange contains a stimulant called
synephrine. Combining bitter orange with
drugs that prolong QT-interval might increase
the risk of arrhythmia; combining with other
stimulants can result in additive stimulant
activity.
Moderate; be cautious with this combination.
Fish oil Antiplatelet/anticoagulant drugs
Orlistat (Xenical, Roche, Nutley,
NJ; Alli, GlaxoSmithKline,
London, United Kingdom)
High-dose fish oils (>3 g/day) can
modestly inhibit platelet aggregation
and might increase the risk of bleeding;
however, there are conflicting data.
Orlistat might decrease the absorption
of fish oils when they are taken
together.
Moderate; be cautious with this combination.
Grape extract Cytochrome P450 1A2 substrations
(eg, Plavix, Bristol-Myers Squibb,
New York, NY; Valium, Roche;
Zyprexa, Eli Lilly and Co,
Indianapolis, Ind; warfarin,
many others)
Grape juice induces cytochrome P450 1A2 drug
metabolism and might decrease levels of
substrates of this enzyme; although grape
juice might interact with these medications, it
is not known whether grape extract has the
same effect.
Moderate; be cautious with this combination.
Stinging nettle Diabetes drugs
Hypertension drugs
Warfarin (Coumadin)
Stinging nettle might lower blood glucose
levels and could have additive effects
when combined with diabetes drugs.
Stinging nettle might lower blood pressure
and could have additive effects when
combined with blood pressure drugs.
Stinging nettle contains vitamin K and
therefore might decrease the
anticoagulant effects of warfarin.
Moderate; be cautious with this combination.
From Jellin J, Gregory P, editors. Natural medicines comprehensive database. Stockton (CA): Therapeutic Research Faculty; 2008. Available at: http://www.naturaldatabase.com.22
Accessed January 1, 2009. Not a complete list. For additional data, go to http://www.naturaldatabase.com.
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liability risk may exist if 1 or more of the following conditions are
met:
1. The referral can be considered negligent because of delay
of diagnosis or accepted treatment32
2. The CAM provider is known to be incompetent and/or the
therapy is ineffective26
3. The physician has exercised supervisory responsibility or
was involved in jointly treating the patient with a provider
known to be incompetent or who has been officially disci-
plined for unsafe practices26,27,30,32
Malpractice cases relating to CAM are less frequent than for
conventional medical therapy.26,32 Should an allegation of med-
ical malpractice be asserted, physicians have 2 major arguments
to raise in their defense. The first defense is the 2 schools of
thought or respectable minority defense, and takes the position
that physicians may choose between alternative approaches to
diagnosis and treatment, ‘‘so long as a respectable minority in
the medical community accepts the alternative approach’’28
(p 192). The definition of respectable minority varies among
courts and jurisdictions.26,28 Competent legal advice should be
sought within the physician’s state of practice for clarification.
The second defense is the assumption of risk argument. This de-
fense asserts that the patient assumes the risk of a particular
treatment and has chosen to relieve the physician of any asso-
ciated liability.28 Although this argument does not completely
eliminate liability for the physician, it can help to decrease mal-
practice exposure. The assumption of risk defense varies widely
by jurisdiction, with some allowing it as a complete defense and
others severely limiting it.27,28 The unanswered ethical question
is, by what right can a provider deny care to patients who exe-
cute their right to choose CAM therapy or therapists despite
negative recommendations? In some cases, competent legal ad-
vice should be sought within the physician’s state of practice for
clarification, and a medical ethics consultation may be also be
considered.
To address concerns related to CAM practices, many state
legislatures have enacted medical freedom acts to assuage
concerns of physicians who choose to practice CAM. However,
such acts vary by state and are a patchwork quilt that does not
adequately change the underlying, parochial nature of medical
practice in the United States. Lasting reform that will serve the
interests of all stakeholders is required. These reforms must
emerge fromwithin the context of the new, integrative health care
environment in which physicians and CAM providers are free to
practice from within their respective philosophical systems. By
fostering interaction, cross-disciplinary research, and collabora-
tive care, redefined standards of care will emerge that are
scientifically based and interdisciplinary in nature. The outgrowth
of such a paradigm shift will change the legal environment from
one of fear to freedom.
In most discussions about the liability risk of CAM therapies
and therapists, there is a remarkable void regarding the fact that
everything advertised on the Internet, on television, in maga-
zines and newspapers, and in the corner grocery store recom-
mends consulting with your physician. If the physician or
provider is committed to the patient and respects the concepts
behind patient-centered care, how can we continue to
TABLE III. Selected natural medicines that can cause or exacerbate atopic conditions
Natural medicine Comment
Anise Inhaled anise can cause rhinoconjunctivitis and asthma in some patients.
Butterbur Some patients can experience pruritus, itchy eyes, and asthma after oral ingestion of butterbur.
Camphor Some patients can experience contact eczema after topical application.
Chlorella Some patients can experience allergic reactions including asthma and anaphylaxis.
Chondroitin One case report linking chondroitin plus glucosamine to exacerbation of asthma.
Chymotrypsin Rare anaphylactic reactions have occurred including dyspnea, urticaria, edema, and others.
Cranberry Cranberry contains a significant amount of salicylic acid; theoretically, large amounts of cranberry could trigger a reaction in patients
with asthma.
Echinacea Allergic reactions to Echinacea are more likely in patients with atopy.
Garlic Allergic reactions associated with garlic include rhinitis, conjunctivitis, urticaria, anaphylaxis, and angioedema.
German chamomile Topical application can cause allergic dermatitis and eczema in some patients.
Glucosamine One case report linking glucosamine plus chondroitin to exacerbation of asthma.
Gotu kola Some patients can experience eczema when gotu kola is applied topically.
Green tea Some patients can experience allergic reactions including cough, dyspnea, and asthma.
Milk thistle Some patients can experience allergic reactions including pruritus, urticaria, eczema, and anaphylaxis.
Pomegranate Topical application can cause contact hypersensitivity in some patients resulting in urticaria, angioedema, rhinorrhea, itchy eyes, and
dyspnea.
Propolis Propolis allergens can worsen asthma symptoms.
Royal jelly Royal jelly causes a high rate of allergic reactions in patients with asthma or atopy. Royal jelly can also worsen symptoms of
dermatitis.
Saffron Rhinoconjunctivitis and asthma has occurred in patients taking saffron.
Schisandra Some patients have experienced allergic skin rashes and urticaria.
Senna Some patients taking senna can experience asthma and allergy symptoms.
Sweet cherry Sweet cherry can cause allergic reactions in sensitive patients such as mucosal irritation, urticaria, angioedema, dyspnea, cough, and
gastrointestinal symptoms.
Tea tree oil Topical application can cause contact eczema in some patients.
Willow bark Willow bark contains a significant amount of salicylic acid; theoretically, willow bark could trigger a reaction in patients with asthma.
From Jellin J, Gregory P, editors. Natural medicines comprehensive database. Stockton (CA): Therapeutic Research Faculty; 2008. Available at: http://www.naturaldatabase.com.22
Accessed December 21, 2008. Not a complete list. For additional data, go to http://www.naturaldatabase.com.
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recommend caution and avoidance, ignoring the need to engage
on CAM therapy questions coming from patients and their
caregivers?33 Perhaps it is time and reasonable to embrace the
following concept:34
Although all discussions need not end in agreement, they
are still opportunities for shared decision making and
relationship-centered care. Ultimately, we should not be
concerned with practicing what is perceived to be tradi-
tional versus alternative and complementary medicine or
biomedicine versus naturalistic medicine but only what is
truly good medicine.34
As in all areas of medicine, competency training is critical to
support high-quality practices. The need for a CAM-relevant
curriculum has become a topic in the literature, with a 2007
publication describing a needs assessment survey in relation to
family practice residents.35 The majority of respondents rarely
ask patients about CAM use, with 92% rating their awareness
of CAM resources as poor or fair in all categories.
IS IT TIME TO CONSIDER EVIDENCE-BASED SAFE
AND EFFECTIVE HERBAL THERAPIES?
The expanding effort to define how and when to incorporate
CAM into patient care has been heavily criticized with a focus on
the existence and funding of the NCCAM at the NIH.36,37 Claims
that nothing has come from this NIH effort are difficult to under-
stand in the face of the growing challenges to physicians and
health care workers with the reality of patient use (whether the
medical establishment approves or not) that will not be contained
by simply ignoring the need. Valuable advances and resources
have been generated from the efforts of the past 10 years. From
traditional Chinese medicine herbal combinations that may fi-
nally provide us a treatment for refractory peanut allergy and
asthma38 to the common cold,39 the healing arts are on an exciting
threshold of advances that many hope will improve the quality of
the care delivered and help to improve care greatly for those
patients who are currently therapeutic orphans.
Remedies for the common cold represent a $17 billion dollar
industry, with Americans spending $2.9 billion annually on over-
the-counter cold preparations and an estimated $1.1 billion in
unnecessary antibiotics.40 The common cold represents the third
most common diagnosis in physicians’ offices according to the
2005 National Ambulatory Medicine Care Survey.41 There is no
well established therapy that has been defined to reducemorbidity
and duration of these viral infections significantly, and approxi-
mately 200 million days of work are lost annually.42 The herbal
remedy known as Pelargonium sidoides, also known as the South
African geranium, available through herbal vendors for years in
health food stores and over the Internet, is associated with a grow-
ing body of evidence supporting its efficacy for the treatment of
the common cold and bronchitis.43,44 It has a biologically plausi-
ble mechanism through induction of the IFN system and upregu-
lation of cytokines important in protecting host cells from viral
infection. The Journal of Family Practice in its popular Priority
Updates from the Research Literature section recommends offer-
ing patients ‘‘Pelargonium sidoides (30 drops 3 times a day) to re-
duce the severity and duration of common cold symptoms and to
get patients back to work sooner.’’ The article even provides a
brand name considered reliable in content, Umcka Coldcare, Na-
ture’sWay, Springville, Utah. Althoughmore research is certainly
needed to clarify the role of this supplement as a potential antibi-
otic-sparing drug, there is also a need to define and document the
range of side effects and even more serious rare adverse reactions
that may become more evident as use increases. As the product is
being licensed in more countries besides Germany with poten-
tially many millions of users in Europe and through over-the-
counter use in the United States, the article by De Boer et al45
inDrug Safety identifies potential safety concerns based on 34 ad-
verse reaction reports including 12 cases of severe, potentially
life-threatening anaphylaxis. Although proof of causality is not
established for each of these cases, the report describes a signal
that merits further study and validation as a potentially increased
risk within an expanded population. It is interesting to speculate
what role the increasing use of herbal supplements might have
in the increasing incidence of anaphylaxis.46-49
CONCLUSION
Complementary and alternative medicine therapy is a growing
part of medical interventions available to and used by the public.
It is unlikely that this reality will change in the future. There is a
need to incorporate substantive but balanced education about
these therapies into continuing education programs as well as
initial medical training in medical schools and residency pro-
grams. Allergy-immunology as a specialty with expertise in
adverse drug reaction diagnosis and management has a unique
opportunity to expand its scope of practice and relevance by
supporting enhanced CAM-related clinical adverse events eval-
uations, reporting, and research.
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TABLE E1. Ten-step approach to physician-patient partnerships in exploring therapeutic alternatives
Step no. Elements of physician-patient interaction Actions and/or special consideration
1 Explore factors driving interest in CAM therapy/therapist
Document instigating factors: current use, intent for future use,
considering future use and seeking information, desire to
access alternative provider
Reasons: desire for greater efficacy, safety, and/or acceptability
Options to engage or not
Support request but indicate limitations of that support, pay-
ment issues, time limits
Refer to another provider for in-depth consultation (may be
difficult to find)*
2 Document clinical reasons for seeking CAM options
Exhausted conventional medicine with unsatisfactory outcomes
Disease with bad prognosis or disability impact
Fear of conventional therapies
Physician-patient perceptions shared
Clinical status, options, and understanding
Need for enhanced care/diagnostics
Need for other therapeutic options
3 Assess current disease/health status and therapies to date
Symptom diary, validated quality of life survey tools
Objective measure of disease (blood pressure, peak flow meter)
Duration of treatment trial
Educates patient about issues
Disease evaluation, treatment options/risks
Acceptance or refusal of partnership (may refer elsewhere,
if possible)
4 Document patient’s preferences and reasons
Reason for CAM therapy choice (if defined by patient)
Attitude toward CAM and conventional medicine
Level of trust in exploring all therapeutic options
Caveats that influence patient’s comfort with discussion/
disclosure
Neutrality of questions asked
Atmosphere: caring/supportive
5 Assess adequacy of medical evaluation (document)
Need for additional testing and/or consultation
Explain all options to optimize diagnosis/treatment
Quality-of-life impact of medical concerns
Provider options or recommendations
Discuss overall risks and benefits of using treatments for which
data are limited
Opportunity for questions, dialogue
6 Define plan for follow-up visits
Agreement between provider and patient regarding therapeutic
partnership: yes or no (with referral rather than refusal
of care)
Consider providing a fact sheet that includes reliable
information and/or other resources about CAM therapy
Provider may opt out of further involvement if available
‘‘evidence indicates serious risk or inefficacy’’
Risk: patient will agree but potentially use anyway
May require out-of-pocket costs for patient
Time for visit may not be covered by existing health insurance
plan
Future visits required with nonreimbursed payment rates (per-
hour rate)
Patient choice may result in provider suggesting move to a new
provider
Challenge: avoiding patient abandonment
7 Provide good risk communication, additional visit options
Define, respectfully and clearly, what physician can do about
request
Determine whether insurance will cover the therapy or time for
consultation on CAM therapy
Define provider’s perception of liability risk concerns
Perspectives: communication optimized if
Honest and caring about patient issues
Explains limitations: time (separate visits), cost-time for
information, risks for provider
Provides alternatives for how to proceed
8 Acknowledge evolving expectations (each visit)
Shared goals for disease and/or symptom control
Detail shared responsibility to gather more information
Establish provider’s ability to support request or validate the
safety and efficacy of the CAM therapy of interest
Clarify the roles of therapy team involved in care management
Consider
Level of patient’s suffering and/or fear
Psychological factors: eg, depression
Patient need for validation, trust
Disclaimers that need to be documented
Ethical considerations in care plan
9 Educate about new safety and/or efficacy issues
Monitor patient and literature concerning specific CAM therapy
trial
Define guidelines for stopping trial, ethical concerns about
supporting continuation of treatment: consider ethics
committee consultation for complex benefit-risk analyses
if controversial
Document patient preferences and understanding of issues
Safety and efficacy: levels of evidence
Communicate balanced clinical considerations: nothing is
risk-free; there are defined/undefined risks
Explain levels of evidence definitions: benefit-risk ratio vs
alternatives?
(Continued )
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TABLE E1. (Continued )
Step no. Elements of physician-patient interaction Actions and/or special consideration
10 Further consultations: critical elements to consider
Discuss factors in choosing a CAM-qualified provider
Address questions of suitability, licensure, competencies*
Document how provider or practice was identified by patient
Educate patient about questions for CAM therapy consultation§
Support of patient seeking input for an informed choice
Empower patient to critically assess treatment trial
Referring provider responsibilities
Document permission to release medical information
Provide disclaimer regarding conflict of interest
Focus on patient choice tempered by benefit-risk considerations
and the concept of ‘‘do no harm’’
Report adverse events, unethical and/or untested practices
Additional information and consideration
Resources available to assess providers*
State certification requirements for CAM therapists
(eg, acupuncture), other resources
Checklist for patient use during CAM visit§
Action items to recommend to patient before starting
unconventional treatment
Education to empower patient choicek
Establish ground rules for appointments: level of continued
physician engagement
MedWatch for reporting adverse events to drugs/devices, use
for CAM reports (http://www.fda.gov/medwatch/)
Adapted and updated from Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997;127:61-9. Comment in: Ann Intern Med 1998;128:328;
author reply 329-30. Ann Intern Med 1998;128:328; author reply 329-30. Ann Intern Med 1998;128:329; author reply 329-30. Ann Intern Med 1998;128:329; author reply 329-30.
*Referral to another provider: What are considerations of such a referral?
Questions to consider: Is this a compassionate trial based on balanced review of all therapies available? Can a patient request for a compassionate trial (even in the absence of
efficacy evidence) be supported by physician/provider?
Support access of patient to information regarding validity, suitability and/or licensure of alternative providers: published literature, clinical trial in progress, state licensure process
available for practitioner type of interest, unbiased sources of information such as NIH/NCCAM (http://nccam.nih.gov/), consumer reports, and so forth.
Educate about conflict of interest considerations: internet search for user experiences, lawsuits, reports of unethical practices with caution about biased testimonials and limitations
of single user experiences, conflicts of interest.
Traditional Medicine Provider: Federation of State Medical Boards, PO Box 619850, Dallas, TX 619850; phone 817-868-4000; fax: 817-868-4099; http://www.FSMB.org.
State certification requirements available for CAM therapists of interest (eg, acupuncture: http://www.acupuncture.com/statelaws/statelaw.htm).
Physician/provider education focus
Establish ground rules for appointments: eg, how many pages of information can the patient bring in for review?
Empower patient to seek more information regarding safety and efficacy of therapies.
Define limits of provider responsibility in the therapeutic trial with therapies outside of conventional practice: ie, buyer beware.
MedWatch for reporting adverse events to drugs/devices, use for CAM reports? http://www.fda.gov/medwatch/.
Strategies to identify reliable, impartial information and data relevant to safety/efficacy of therapy or providers
Natural Medicines Comprehensive Database consumer information sheets on individual herbs or supplements.
Information resources that represent unconflicted independent reviewers (eg, Consumer Reports, Cochrane Database Reports).
Guidelines for use of CAM in medical practice at http://www.fsmb.org/pdf/2002_grpol_Complementary_Alternative_Therapies.pdf. Accessed December 1, 2008.
§Questions patients should ask their CAM therapy practitioners
Is the provider’s belief in the effectiveness of the therapy (for example, acupuncture) based on clinical experience with similar patients? How many patients have received the
treatment, and what was their outcome (the good and bad)?
What will the therapy consist of? What is the recommended frequency and duration of therapy? What are the known side effects and serious adverse events?
What is the cost of evaluation and therapy trials? Is third-party reimbursement available?
What criteria will be used and when to assess therapy benefit or failure? How many patients have received treatment and how many got better, worse, or had no change? Beware
of 100% or 0% because these statistics are never true and raise suspicion.
Are there written instructions about the treatments and how success or failure will be defined by the CAM therapist?
Is the provider willing to communicate diagnostic findings, therapeutic plans, and follow-up with the patient’s primary care provider and/or specialist? Are there any limitations to
this communication? Who actually administers the therapy?
kAction items to recommend to patient before starting unconventional treatments
Talk to other patients who have been treated and search the Internet for experiences related to this provider by other patients.
Ask for written instructions about the treatments and how success or failure will be defined by CAM therapist.
Search for specifics about side effects using such resources as the Natural Medicines Comprehensive Database and the published medical literature via PubMed.
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TABLE E2. Criteria for Natural Medicines Comprehensive Database evidence-based safety ratings and effectiveness ratings
Evidence-based criteria for safety ratings
Likely Safe: Product has a very high level of reliable clinical evidence showing its safe use when used appropriately. Products rated likely safe are generally
considered appropriate to recommend. To achieve this safety rating, a product is supported by all of the following:
Safety data are available from multiple (21) randomized clinical trials or meta-analysis or large-scale postmarketing surveillance including several hundred
patients (level of evidence5 A), or the product has undergone a safety review consistent with or equivalent to passing a review by the FDA, Health Canada,
or a similarly rigorous approval process.
Studies have a low risk of bias and a high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Studies adequately measure and report safety and adverse outcomes data and consistently show no significant serious adverse effects without valid evidence to
the contrary.
Possibly Safe: Product has some clinical evidence showing its safe use when used appropriately; however, the evidence is limited by quantity, quality, or
contradictory findings. Products rated possibly safe appear to be safe, but do not have enough high-quality evidence to recommend for most people. To
achieve this safety rating, a product is supported by all of the following:
Safety data are available from 1e or more randomized clinical trials, meta-analysis (level of evidence 5 A or B), case series, 2 or more population based or
epidemiologic studies (level of evidence 5 B), or limited postmarketing surveillance data.
Studies have a low to moderate risk of bias and moderate to high level of validity by meeting or partially meeting assessment criteria (quality rating A or B).
Studies adequately measure and report safety and adverse outcomes data and show no significant serious adverse effects without substantial evidence to the
contrary. Some contrary evidence may exist; however, valid evidence supporting safety outweighs contrary evidence.
Possibly Unsafe: Product has some clinical evidence showing safety concerns or significant adverse outcomes; however, the evidence is limited by quantity,
quality, or contradictory findings. People should be advised not to take products with a possibly unsafe rating. To achieve this safety rating, a product is
supported by all of the following:
Safety data are available from 1 or more randomized clinical trials, meta-analysis (level of evidence 5 A or B), 2 or more population-based or epidemiologic
studies (level of evidence 5 B), or limited postmarketing surveillance data. Or multiple, reliable case reports show a potential causal relationship between a
product and serious adverse outcome.
Studies have a low to moderate risk of bias and moderate to high level of validity by meeting or partially meeting assessment criteria (quality rating A or B).
Studies adequately measure and report safety and adverse outcomes data and show significant serious adverse effects without substantial evidence to the
contrary. Some contrary evidence may exist; however, valid evidence supporting potential safety concerns outweighs contrary evidence.
Likely Unsafe: Product has a very high level of reliable clinical evidence showing safety concerns or significant adverse outcomes. People should be
discouraged from taking products with a likely unsafe rating. To achieve this safety rating, a product is supported by all of the following:
Safety data are available from multiple (21) randomized clinical trials, meta-analysis, or large-scale postmarketing surveillance including several hundred
patients to several thousand patients (level of evidence 5 A).
Studies have a low risk of bias and high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Studies adequately measure and report safety and adverse outcomes data and consistently show significant serious adverse effects without valid evidence to the
contrary.
Unsafe: This product has a very high level of reliable clinical evidence showing safety concerns or significant adverse outcomes. People should be discouraged
from taking products with an unsafe rating. To achieve this safety rating, a product is supported by all of the following:
Safety data are available from multiple (21) randomized clinical trials, meta-analysis, or large-scale postmarketing surveillance including several hundred to
several thousand patients (level of evidence 5 A).
Studies have a low risk of bias and high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Studies adequately measure and report safety and adverse outcomes data and consistently show significant serious adverse effects without valid evidence to the
contrary.
Evidence-based criteria for efficacy ratings
Effective: This product has a very high level of reliable clinical evidence supporting its use for a specific indication. Products rated effective are generally
considered appropriate to recommend. To achieve this effectiveness rating, a product is supported by all of the following:
Evidence consistent with or equivalent to passing a review by the FDA, Health Canada, or similarly rigorous approval process.
Evidence from multiple (21) randomized clinical trials or meta-analysis including several hundred to several thousand patients (level of evidence 5 A).
Studies have a low risk of bias and high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Evidence consistently shows positive outcomes for a given indication without valid evidence to the contrary.
Likely Effective: This product has a very high level of reliable clinical evidence supporting its use for a specific indication. Products rated likely effective are
generally considered appropriate to recommend. To achieve this effectiveness rating, a product is supported by all of the following:
Evidence from multiple (21) randomized clinical trials or meta-analysis including several hundred patients (level of evidence 5 A).
Studies have a low risk of bias and high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Evidence consistently shows positive outcomes for a given indication without significant valid evidence to the contrary.
Possibly Effective: This product has some clinical evidence supporting its use for a specific indication; however, the evidence is limited by quantity, quality, or
contradictory findings. Products rated possibly effective might be beneficial, but do not have enough high-quality evidence to recommend for most people.
To achieve this effectiveness rating, a product is supported by all of the following:
One or more randomized clinical trials or meta-analysis (level of evidence 5 A or B) or 2 or more population based or epidemiologic studies (level of
evidence 5 B).
Studies have a low to moderate risk of bias and moderate to high level of validity by meeting or partially meeting assessment criteria (quality rating A or B).
Evidence shows positive outcomes for a given indication without substantial valid evidence to the contrary. Some contrary evidence may exist; however, valid
positive evidence outweighs contrary evidence.
(Continued )
J ALLERGY CLIN IMMUNOL
VOLUME 123, NUMBER 2
ENGLER ET AL 316.e3
TABLE E2. (continued )
Evidence-based criteria for efficacy ratings
Possibly Ineffective: This product has some clinical evidence showing ineffectiveness for a specific indication; however, the evidence is limited by quantity,
quality, or contradictory findings. People should be advised not to take products with a possibly ineffective rating. To achieve this effectiveness rating, a
product is supported by all of the following:
One or more randomized clinical trials or meta-analysis (level of evidence 5 A or B) or 2 or more population-based or epidemiologic studies (level of
evidence 5 B).
Studies have a low to moderate risk of bias and moderate to high level of validity by meeting or partially meeting assessment criteria (quality rating A or B).
Evidence shows negative outcomes for a given indication without substantial valid evidence to the contrary. Some contrary evidence may exist; however, valid
positive evidence outweighs contrary evidence.
Likely ineffective: This product has a very high level of reliable clinical evidence showing ineffectiveness for its use for a specific indication. People should be
discouraged from taking products with a likely ineffective rating. To achieve this effectiveness rating, a product is supported by all of the following:
Evidence from multiple (21) randomized clinical trials or meta-analysis including several hundred patients (level of evidence 5 A).
Studies have a low risk of bias and high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Evidence consistently shows negative outcomes for a given indication without significant valid evidence to the contrary.
Ineffective: This product has a very high level of reliable clinical evidence showing ineffectiveness for its use for a specific indication. People should be
discouraged from taking products with an ineffective rating. To achieve this effectiveness rating, a product is supported by all of the following:
Evidence from multiple (21) randomized clinical trials or meta-analysis including several hundred to several thousand patients (level of evidence 5 A).
Studies have a low risk of bias and high level of validity by meeting stringent assessment criteria (quality rating 5 A).
Evidence consistently shows negative outcomes for a given indication without valid evidence to the contrary.
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